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Current Tax Laws
and R & D
Opportunity and Incentive

By Mary Lynn Siegler

The Economic Recovery Act has
made many changes to the current tax
laws. One such change was the addi
tion of a credit against tax for research
expenses made after June 30, 1981
and before January 1,1986. This new
law (Section 44F) was designed to en
courage companies to perform more
research and development. As a result
of this encouragement, many com
panies are consulting their account
ants to find out how they can benefit
from the research credit. One such in
quiry is described below.
Corporation X has decided to spend
a portion of the company’s profits on
research and development (R&D).
They do not have the inhouse facilities
with which to perform the needed
research and therefore find it neces
sary to contract for these services.
A 78 percent stockholder (E) of Cor
poration X has proposed that he form
a partnership with N and that the E-N
Partnership perform the needed R&D
for X Corporation. N is an engineer and
has experience in the R&D field.
Because E&N do not have the
money to fund the needed R&D on
their own, X Corporation will sign a
contract with E-N which stipulates that

X make regular payments to E-N in
return for the first right to purchase any
patents obtained by E-N as a result of
the R&D performed for X.
X Corporation wants to know what
the tax consequences of this plan
would be and what changes to the plan
could be made in order to lower the
taxes of both Corporation X and Part
nership E-N.

Section 44F—Credit for Research
Activities
To answer these questions, Code
Section 44F was researched first. This
section allows as a credit against tax;
“an amount equal to 25% of the ex
cess (if any) of—
(1) the qualified research expenses
for the taxable year, over
(2) the base period research ex
penses.” (Sec. 44F(a))
Qualified research expenses are ex
penses paid or incurred by the tax
payer while carrying on any trade or
business for in-house research and
contract research expenses. (Sec.
44F(b)) However, there are certain
restrictions on amounts paid for con
tract research as follows:

(1) Only 65% of amounts paid for
contract research expenses are
considered qualified research
expenses for the purpose of
calculating the credit. (Sec.
44F(b))
(2) Amounts paid to others for R&D
qualify for the credit only if they
are pursuant to a written re
search agreement between the
parties. (Sec. 44F(e))
(3) The organization performing the
contract research must, accord
ing to Sec. 44F(e), be;
(a) any educational organization
which is described in section
170(b) (1) (A) (ii) and which
is an institution of higher
education (as defined in sec
tion 3304(f), or
(b) any other organization
which—
(i) is described in section
501(c) (3) and exempt
from tax under section
501(a).
(ii) is organized and oper
ated primarily to con
duct scientific research,
and
(iii) is not a private founda
tion.

Therefore, it would appear from ex
amining Section 44F that X Corpora
tion would be allowed to use 65
percent of the amount it pays to E-N
Partnership in calculating the tax credit
as long as Corp. X has a written re
search agreement with E-N.
In order to obtain a credit, X must
have expenses during the taxable year
which exceed the base period re
search expenses. The base period
research expenses are arrived at by
taking the qualified research expenses
for the three immediately preceding
tax years and averaging them. Special
rules apply to calculating the base
period research expenses when the
credit is taken for years beginning in
1980-1982. (Sec. 44F(c)) In no event
shall the base period research ex
penses be less than 50 percent of the
qualified research expenses for the
determination year. (Sec. 44F(c))

This translates to a maximum credit
of 8.125 percent of qualified research
expenditures of X Corp., as shown in
the following computation.
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Payments to E-N Partnership
Amount allowable for
contract services

Qualified research expenses
Minimum base period re
search expenses (65x50%)
Credit

100

65%
65
(32.5)
32.5
25%
8.125%

In addition, the credit is limited to the
tax liability for the taxable year reduced
by other credits. However, it may be car
ried back three and forward 15 years.
(Sec. 44F(g))
The credit is only available for expen
ditures made after June 30, 1981 and
before January 1, 1986.
Section 44F has one other restriction
applicable to X Corp. which is spelled
out in the Committee Reports on the
Economic Recovery Act.1
‘‘The credit is not available for any
activity performed for another person
(or governmental entity), whether pur
suant to a grant, contract, or otherwise.
Thus, if a taxpayer contracts with a re
search firm, university, or other person
for research to be performed on the
taxpayer’s behalf, only the taxpayer
which makes payments under the re
search contract and on whose behalf
the research is conducted can claim
the credit as to those expenditures; the
research firm, university, or other per
son which conducts the research on
behalf of the taxpayer cannot claim any
credit for its expenditures in perform
ing the contract.”

Therefore, only Corp. X is qualified to
take the credit. However, E-N would still
be able to benefit from R&D expense
deductions allowed under Section 174.
Section 174—Research and
Experimental Expenditures
Section 174 allows a taxpayer to treat
as expenses any research or experi
mental expenditures paid or incurred in
connection with his trade or business.
(Sec. 174(a)) Regulation 1.1.74-2 states;
‘‘The term ‘research or experimental
expenditures, ’ as used in section 174,
means expenditures incurred in con
nection with the taxpayer’s trade or
business which represent research and
development costs in the experimental
or laboratory sense. The term includes
generally all such costs incident to the
development of an experimental or pilot
model, a plant process, a product, a
formula, an invention, or similar prop
erty, and the improvement of already
existing property of the type mentioned.
The term does not include expenditures
such as those for the ordinary testing
or inspection of materials or products
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for quality control or those for efficiency
surveys, management studies, con
sumer surveys, advertising, or promo
tions. However, the term includes the
costs of obtaining a patent, such as at
torneys’ fees expended in making and
perfecting a patent application. On the
other hand, the term does not include
the costs of acquiring another’s patent,
model, production or process, nor does
it include expenditures paid or incurred
for research in connection with literary,
historical, or similar projects.
The provisions of this section apply
not only to costs paid or incurred by
the taxpayer for research or experi
mentation undertaken directly by him
but also to expenditures paid or in
curred for research or experimenta
tion carried on in his behalf by
another person or organization (such
as a research institute, foundation,
engineering company, or similar
contractor). ”

Thus, it is permissable for both Corp.
X and Partnership E-N to deduct as ex
penses the allowable “research or ex
perimental expenditures”. For X, this
would be the amounts paid to E-N. For
E-N, this would be the costs incurred
in performing R&D for Corp. X, which
would offset the income received from
X.
After substantial R&D expenses,
Partnership E-N hopes to have devel
oped plans for a new or improved prod
uct which can be patented. They also
hope that Corp. X will want to purchase
the patent.
In considering the tax consequences
of the sale of the patent, it is necessary
to look at Section 1235 of the 1954
Code.
Section 1235—Sale or Exchange of
Patents

Section 1235(a) states that the sale
of a patent qualifies for capital gains
treatment if:
(1) all substantial rights to the pa
tent are transferred,
(2) by a holder of the patent,
(3) to an unrelated party.
Reg. 1.1235-2(b) defines “all sub
stantial rights” as follows:
‘‘The term ‘all substantial rights to a
patent’ means all rights (whether or
not then held by the grantor) which
are of value at the time the rights to
the patent (or an undivided interest
therein) are transferred. The term ‘all
substantial rights to a patent’ does
not include a grant of rights to a
patent—

(i) Which is limited geographically
within the country of issuance;
(ii) Which is limited in duration by
the terms of the agreement to a
period less than the remaining life of
the patent;
(Hi) Which grants rights to the
grantee, in fields of use within trades
or industries which are less than all
the rights covered by the patent,
which exist and have value at the
time of the grant;
(iv) Which grants to the grantee
less than all the claims or inventions
covered by the patent, which exist
and have value at the time of the
grant,
The circumstances of the whole
transaction, rather than the particular
terminology used in the instrument of
transfer, shall be considered in deter
mining whether or not all substantial
rights to a patent are transferred in a
transaction.
(2) Rights which are not con
sidered substantial for purposes of
section 1235 may be retained by the
holder. Examples of such rights are:
(i) The retention by the transferor of
legal title for the purpose of securing
performance or payment by the
transferee in a transaction involving
transfer of an exclusive license to
manufacture, use, and sell for the life
of the patent:
(ii) The retention by the transferor
of rights in the property which are not
inconsistent with the passage of
ownership, such as the retention of
a security interest (such as a vendor’s
lien), or a reservation in the nature of
a condition subsequent (such as a
provision for forfeiture on account of
nonperformance).
(3) Examples of rights which may
or may not be substantial, depending
upon the circumstances of the whole
transaction in which rights to a patent
are transferred, are:
(i) The retention by the transferor of
an absolute right to prohibit sub
licensing or subassignment by the
transferee;
(ii) The failure to convey to the
transferee the right to use or to sell
the patent property.
(4) The retention of a right to ter
minate the transfer at will is the reten
tion of a substantial right for the pur
poses of section 1235.”

The term “holder” as defined by
Reg. 1.1235-2(d) is any individual who
invented the patent property. In the
case of a partnership, each member of
the partnership is a holder.
Partnership E-N will have no prob

lems in satisfying the first two re
quirements of Sec. 1235. However, the
last requirement of Sec. 1235, that the
sale must be to an unrelated party, will
disqualify the sale from receiving
capital gains treatment under Sec.
1235. Partner E is a 78 percent stock
holder of Corp. X and Reg. 1.1235-2(f)
states that;
“If, subsequent to September 2,
1958, a holder transfers all his sub
stantial rights to a patent to a corpora
tion in which he owns 25 percent or
more in value of the outstanding
stock, he is considered as transfer
ring such rights to a related person
for the purpose of section 1235. ’’

Therefore, according to Sec. 1235,
upon sale of the patent to Corp. X,
Partner N would receive capital gains
treatment on his one half of the patent.
Partner E would be required to claim
ordinary income for the sale proceeds
of his one half.
However, Partner E has another op
tion available for obtaining capital gain
treatment. The Regulations state that
“a transfer by a holder to a related per
son is not governed by section 1235”
and is determined under other provi
sions of the internal revenue laws.
(Reg. 1.1235-2(f)) The IRS has reaf
firmed this position; it states in
Revenue Ruling 69-4822 that,
“The mere fact that a patent
transfer for contingent amounts does
not qualify for long-term capital gains
treatment under Code Sec. 1235 will
not prevent it from qualifying for such
treatment under other provisions of
the Code. ”

Therefore, because the patent is a
depreciable capital asset, the sale can
qualify for capital gains treatment
under Sec. 1221 as long as the provi
sions of Sec. 1239 do not apply and
cause ordinary income treatment of
the gain.
Section 1239—Sales Between Related
Parties
For sales of depreciable property,
code section 1239(b) states that any
gain should be treated as ordinary in
come if the sale is between a taxpayer
and his 80 percent owned entity.
Section 1239(c) defines an 80 per
cent owned entity as a corporation in
which the taxpayer owns 80 percent or
more in value of the outstanding stock.
For the purposes of this section fami
ly attribution rules apply only to the in
dividual and his or her spouse.
It would appear from this definition

that the sale of the patent by E-N to X
would not fall under Sec. 1239 and that
Partner E would be able to receive
capital gains treatment for his portion
of the gain on the sale.
However, in applying the 80 percent
test, the Court of Appeals for the Fifth
Circuit has interpreted the words “in
value” to mean more than merely the
number of shares or the voting power.
In “C.L. Parker”3, the court found that
even though Parker owned exactly 80
percent of the outstanding stocks and
Eaves owned exactly 20 percent that
Parker owned more than 80 percent in
value of the corporation’s outstanding
stock.

outstanding stock. He treated the
transaction as a sale of a capital asset
and took capital gains treatment on his
tax return. A U.S. District Court first
found that Dahlgren’s treatment of the
sale was correct based on his 79.5 per
cent ownership of the outstanding
stock. The U.S. Court of Appeals at
New Orleans reversed and remanded
the decision of the U.S. District Court.
In its conclusion, the U.S. Court of Ap
peals stated that;

Parker had sold depreciable assets
to his 80 percent owned corporation
and had elected to treat the sale as a
capital transaction. The court noted
that, because Parker owned exactly 80
percent of the outstanding stock,

In “E.L. Parker”3 the courts em
phasized the importance of Section
1239.

“if any fact can be found which
shows that the value per share of
Parker’s stock exceeded by any
amount, no matter how small, the
value per share of Eaves’s, then
Parker, owned more than 80 percent
in value of the outstanding stock.’’3

The court then determined that,
because Parker owned the controlling
interest of the corporation, his stock
represented more than 80 percent in
value of the corporation.
“Parker controlled without possi
bility of challenge the entire operation
from the smallest detail to the largest.
He exercised so much power that the
corporation was his alter ego, or his
slave. This is the situation at which
1239 aims.
Any purchaser of Eaves’ stock
would not be buying any degree of
control over the corporation. The
voting power which technically in
hered in Eaves’s stock was in reality
worthless; Parker owned all of the
real voting stock.
We hold that this disability which
inhered in Eaves’s stock reduced its
value per share below that of Parker’s
stock as a matter of law. ”3

Therefore, the sale of the depreci
able assets was ruled to fall under Sec
tion 1239 and the gain was taxed as
ordinary income.
The court has upheld this 80 percent
in value decision in “E.L. Childers”4 in
1974 and again in “H.P. Dahlgren”5 in
1977.
In the Dahlgren case, Dahlgren sold
his interest in a patent to a corporation
in which he owned 79.5 percent of the

“the trial court erred in not charging
the jury on the important issue pre
sented by the “Parker principle”
touching on the inherent added value
increment in a controlling block of
stock. ”5

“Section 1239 prevents capital
gain treatment of a ‘sale or exchange’
of depreciable property to a con
trolled corporation or a spouse. With
out this section a taxpayer who had
property which had been depreciated
to a low basis could sell that property
to a controlled corporation or spouse
and pay only capital gains rates on
the gain. The transferee (who is virtu
ally identical to the transferor in the
proscribed area) could then redepre
ciate the property, using the sale
price as a new basis. The deprecia
tion, of course, would be deducted
from ordinary income. Section 1239
renders such a scheme profitless by
taxing the gain on the transfer at or
dinary rather than capital rates.’’3

In light of these court decisions, it is
likely that the sale of the patent by EN to X would come under Section 1239
for Partner E by virtue of his 78 per
cent ownership of the outstanding
stock carrying a value of 80 percent or
more in the corporation.
One way to avoid this would be for
E to sell to one of his children a por
tion of his stock so that the value of the
outstanding stock owned by E would
be less than 80 percent. This is possi
ble because after October 19, 1980,
the family attribution rules apply only
to husbands and wives.6 However, it
would be difficult to determine how
much he should sell in order to
decrease the value of his ownership
value below 80 percent. Also, share
holder E has expressed that he does
not wish to give up any of his stock
ownership if there is any other way that
he may achieve capital gains treat
ment on the sale of the patent.
There is one other possibility for
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escape from falling under Section
1239. That is for Partnership E-N not
to patent the invention before sale to
Corp. X. An unpatented invention is
not a depreciable asset because of an
indeterminate useful life and therefore
does not fall under Section 1239. It
also does not come under Section
1235. Therefore, the seller can be a
100 percent owner of the corporation
to which he is selling his unpatented
invention and receive capital gains
treatment on the sale. Also, after ob
taining the patent, Corp. X will be able
to depreciate the cost of purchasing
the invention plus any costs incurred
in obtaining the patent.7
However, Partnership E-N must be
careful, if a patent application has
been made, to sell the patent applica
tion to Corp. X before it is evident that
the patent will be allowed.
In “Estate of Stahl v. Commis
sioner” (1971)8 the taxpayer sold to his
wholly-owned corporation various (1)
patents, (2) patent applications to
which notices of allowance or indica
tions of allowability had been received
prior to transfer, and (3) patent applica
tions which had, prior to transfer, been
rejected by the Patent Office. The
court ruled that the patent applications
which were allowed or which had in
dications of allowability from the Patent
Office ((2) above) had “matured” into
depreciable assets and thus, along
with the patents, were subject to Sec
tion 1239 and the gains were taxed as
ordinary income. However, the patent
applications which were rejected ((3)
above) were not depreciable and
therefore the gains were taxed at
capital gain rates.

(6) The Patent Office adhered to its
previous position.
(7) On December 18, 1959, Chu
sold his interest in the patent ap
plication to Chu Associates, Inc.
Chu owned 80% of the out
standing stock on that date.
(8) On March 8, 1960, Chu Asso
ciates, Inc. filed Amendment C.
(9) On September 7, 1960 the Pa
tent Office allowed all 18 claims.
The Court ruled that the patent ap
plications were not depreciable assets
and therefore escaped Section 1239.
The court stated that;
“we must not forget that not every pa
tent application is ultimately ap
proved. Consequently, were we to
apply the interpretation of 1239
sought by the government, the inven
tor who has the misfortune to trans
fer a patent application that is
subsequently disapproved would
face the worst of both possible
worlds: he would pay ordinary in
come rates on his initial gain from the
transfer, while his controlled corpora
tion would never be able to take any
depreciable deduction against or
dinary income. It would be entirely
rational, therefore, for Congress to
conclude that 1239 should apply only
in those instances where the dangers
of tax abuse were most acute (i.e. the
transfer to a controlled corporation of
depreciable property), while denying
1239 treatment to situations where
unwarranted tax results might
occur.”9

Conclusion
In order for Corporation X and Part
nership E-N to obtain the maximum
benefits from the tax code concerning
Research and Development expendi
tures, they should follow the plan out-

In “L.J. Chu”9 the following facts
were presented:

(1) On June 26, 1956, Chu filed an
application with the U.S. Patent
Office seeking a patent on a new
antenna. The application involv
ed claims 1-18.
(2) On July 5, 1957, the Patent Of
fice disallowed claims 1-13 but
indicated allowability of claims
14-18.
(3) On December 9,1957, Chu filed
an Amendment A.
(4) The Patent Office responded
that in addition to claims 14-18,
claim 12 also appeared
allowable.
(5) On September 14, 1959,
Amendment B was filed.
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lined below:
I. Form Partnership E-N to conduct
R&D for Corp. X.
A. Corp. X will be eligible to take
the credit for Research Activities
under Sec. 44F for 65 percent of
amounts paid to E-N. E-N is not
eligible.
1. Be certain to have a written
contract between X & E-N.
B. Corp. X and Partnership E-N
may both deduct R&D expendi
tures under Sec. 174.
1. For X, this is the amount paid
to E-N.
2. For E-N, this is the amount
expended in carrying on
R&D.
II. Sale of Invention by Partnership EN to Corp. X.
A. Sale should be completed before
an indication of allowability of pa
tent is received.
1. The unpatented invention is
not a depreciable asset and
Section 1239 will not apply.
2. The gain on the sale will be
capital gains to Partners E &
N.
B. If patent is obtained;
1. Partner N will still receive
capital gains treatment under
Sec. 1235.
2. Partner E will have to claim
the gain as ordinary income
because he will not meet the
requirements of Sec. 1235.
He is selling the patent to a
related party.
a. Partner E could sell a por
tion of his stock to one of
his children and meet the
requirements of Sec.
1235.
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